776 related articles for article (PubMed ID: 17984166)
1. Rosuvastatin in older patients with systolic heart failure.
Kjekshus J; Apetrei E; Barrios V; Böhm M; Cleland JG; Cornel JH; Dunselman P; Fonseca C; Goudev A; Grande P; Gullestad L; Hjalmarson A; Hradec J; Jánosi A; Kamenský G; Komajda M; Korewicki J; Kuusi T; Mach F; Mareev V; McMurray JJ; Ranjith N; Schaufelberger M; Vanhaecke J; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
N Engl J Med; 2007 Nov; 357(22):2248-61. PubMed ID: 17984166
[TBL] [Abstract][Full Text] [Related]
2. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
Cleland JG; McMurray JJ; Kjekshus J; Cornel JH; Dunselman P; Fonseca C; Hjalmarson A; Korewicki J; Lindberg M; Ranjith N; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
J Am Coll Cardiol; 2009 Nov; 54(20):1850-9. PubMed ID: 19892235
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.
Ueland T; Dahl CP; Kjekshus J; Hulthe J; Böhm M; Mach F; Goudev A; Lindberg M; Wikstrand J; Aukrust P; Gullestad L
Circ Heart Fail; 2011 Mar; 4(2):145-52. PubMed ID: 21216833
[TBL] [Abstract][Full Text] [Related]
5. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
6. [No reason to start treatment with statins in patients with moderate to severe heart failure].
Stalenhoef AF
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):486-8. PubMed ID: 18389878
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
Carter NJ
Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
[TBL] [Abstract][Full Text] [Related]
8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
10. [To treat or not to treat with statins patients with chronic heart failure?].
Hradec J
Vnitr Lek; 2009 Sep; 55(9):802-7. PubMed ID: 19785380
[TBL] [Abstract][Full Text] [Related]
11. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.
Shepherd J; Vidt DG; Miller E; Harris S; Blasetto J
Cardiology; 2007; 107(4):433-43. PubMed ID: 17363845
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
Fellström BC; Jardine AG; Schmieder RE; Holdaas H; Bannister K; Beutler J; Chae DW; Chevaile A; Cobbe SM; Grönhagen-Riska C; De Lima JJ; Lins R; Mayer G; McMahon AW; Parving HH; Remuzzi G; Samuelsson O; Sonkodi S; Sci D; Süleymanlar G; Tsakiris D; Tesar V; Todorov V; Wiecek A; Wüthrich RP; Gottlow M; Johnsson E; Zannad F;
N Engl J Med; 2009 Apr; 360(14):1395-407. PubMed ID: 19332456
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A
J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
Gullestad L; Ueland T; Kjekshus J; Nymo SH; Hulthe J; Muntendam P; Adourian A; Böhm M; van Veldhuisen DJ; Komajda M; Cleland JG; Wikstrand J; McMurray JJ; Aukrust P;
Eur Heart J; 2012 Sep; 33(18):2290-6. PubMed ID: 22513778
[TBL] [Abstract][Full Text] [Related]
15. [Statin therapy for systolic heart failure. The CORONA trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)].
Angermann CE; Nitschmann S
Internist (Berl); 2008 Jul; 49(7):884-6. PubMed ID: 18427760
[No Abstract] [Full Text] [Related]
16. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
Tavazzi L; Maggioni AP; Marchioli R; Barlera S; Franzosi MG; Latini R; Lucci D; Nicolosi GL; Porcu M; Tognoni G;
Lancet; 2008 Oct; 372(9645):1231-9. PubMed ID: 18757089
[TBL] [Abstract][Full Text] [Related]
17. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
[TBL] [Abstract][Full Text] [Related]
19. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
Askevold ET; Nymo S; Ueland T; Gravning J; Wergeland R; Kjekshus J; Yndestad A; Cleland JG; McMurray JJ; Aukrust P; Gullestad L
Circ Heart Fail; 2013 Jan; 6(1):91-8. PubMed ID: 23230311
[TBL] [Abstract][Full Text] [Related]
20. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Kones R
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
